NUCC-0226272

NUCC-0226272 is a potent PROTAC that targets EZH2 for degradation. NUCC-0226272 has anti-proliferative effect. NUCC-0226272 has the potential for cancer research[1].

Product Specifications

CAS Number

[3004503-12-9]

UNSPSC

12352005

Target

Histone Methyltransferase; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nucc-0226272.html

Purity

99.68

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCN(C1CCOCC1)C2=CC(C3=CC=C(C=C3)CN4CCN(CC4)C(CCCCCCCCCC(N[C@@H](C(C)(C)C)C(N5[C@@H](C[C@H](C5)O)C(NCC6=CC=C(C7=C(N=CS7)C)C=C6)=O)=O)=O)=O)=CC(C(NCC8=C(C=C(NC8=O)C)C)=O)=C2C

Molecular Formula

C67H91N9O8S

Molecular Weight

1182.56

References & Citations

[1]Gary E. Schiltz, et al. Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (ezh2) and proteolysis-targeting chimeric derivatives thereof (protacs) that induce degradation of ezh2. US20230346953A1.